ClinicalTrials.gg

Program

brensocatib

Also written as “Brensocatib”, “Brensocatib 10 mg” and “Brensocatib 25 mg”.

Its studies are mostly in Bronchiectasis · Nasal Polyps · Hidradenitis Suppurativa · Cystic Fibrosis · Renal Insufficiency, led by 2 companies.

Furthest: phase 3, since Oct 14, 202017 company-led studies, 1 open or runningNext primary completion: Nov 25, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Insmed151 open or runningphase 3since Oct 14, 2020Jul 11, 2017Nov 25, 2026phase 1 · NCT07859007
AstraZeneca20 open or runningphase 1since Nov 3, 2014Nov 3, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Nov 3, 2014.

  1. Jul 11, 2017Insmed's first study: phase 2 study in BronchiectasisNew to InsmedInsmed · NCT03218917 · 256 enrolled · United States, Australia, Belgium and more
  2. Oct 14, 2020Phase 3 study in Non-Cystic Fibrosis BronchiectasisInsmed · NCT04594369 · 1,767 enrolled · United States, Argentina, Australia and more
  3. Oct 14, 2021Phase 2 study in Cystic FibrosisInsmed · NCT05090904 · 29 enrolled · United States
  4. Apr 26, 2022Phase 1 study in Healthy VolunteerInsmed · NCT05355935 · 48 enrolled · United States
  5. Aug 24, 2022Phase 1 study in Hepatic ImpairmentInsmed · NCT05517525 · 30 enrolled · United States
  6. Dec 7, 20222 phase 1 studiesInsmed · NCT05652257, NCT05673603
  7. Apr 12, 2023Phase 1 study in Healthy VolunteersInsmed · NCT05826574 · 32 enrolled · United States
  8. Jun 22, 2023Phase 1 study in Healthy VolunteersInsmed · NCT05927597 · 82 enrolled · United States
  9. Jul 19, 2023Phase 1 study in Healthy VolunteersInsmed · NCT05965570 · 22 enrolled · United States
  10. Aug 22, 2023Phase 2 study in Chronic Rhinosinusitis Without Nasal PolypsInsmed · NCT06013241 · 288 enrolled · United States, Argentina, Australia and more
  11. Dec 12, 2023Phase 1 study in Healthy VolunteersInsmed · NCT06178783 · 20 enrolled · United States
  12. Mar 27, 2024Phase 1 study in Healthy ParticipantsInsmed · NCT06344728 · 24 enrolled · United States
  13. Nov 11, 2024Phase 2 study in Hidradenitis SuppurativaInsmed · NCT06685835 · 214 enrolled · United States, Australia, Bulgaria and more
  14. Sep 29, 2026Phase 1 study in Healthy VolunteersInsmed · NCT07859007 · 26 planned

Ahead

  1. Nov 25, 2026Primary completion: phase 1 study in Healthy VolunteersInsmed · NCT07859007

TargetBeta

CTSC →read by rule
“An orally bioavailable, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), ”NCIt, by rule
“Dipeptidyl peptidase I inhibitor”ChEMBL 37, by rule

Other programs on CTSC

ProgramCompanyFurthest phaseStudies
verducatibBoehringer Ingelheimphase 321
RSS0343Jiangsu HengRui Medicinephase 24

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07859007Healthy Volunteers1Not yet recruitingInsmedNov 25, 202626
NCT06685835Hidradenitis Suppurativa · United States, Australia, Bulgaria and more2TerminatedInsmedFeb 12, 2026214
NCT06344728Healthy Participants · United States1CompletedInsmedMay 24, 202424
NCT06178783Healthy Volunteers · United States1CompletedInsmedJan 4, 202420
NCT06013241Chronic Rhinosinusitis Without Nasal Polyps · United States, Argentina, Australia and more2CompletedInsmedSep 30, 2025288
NCT05965570Healthy Volunteers · United States1CompletedInsmedSep 22, 202322
NCT05927597Healthy Volunteers · United States1CompletedInsmedAug 1, 201982
NCT05826574Healthy Volunteers · United States1CompletedInsmedJul 16, 202332
NCT05673603Renal Insufficiency · United States1CompletedInsmedFeb 14, 202328
NCT05652257Healthy Volunteers · United States1CompletedInsmedSep 14, 20217
NCT05517525Hepatic Impairment · United States1CompletedInsmedJun 1, 202330
NCT05355935Healthy Volunteer · United States1CompletedInsmedOct 7, 202248
NCT05090904Cystic Fibrosis · United States2CompletedInsmedNov 1, 202229
NCT04594369Non-Cystic Fibrosis Bronchiectasis · United States, Argentina, Australia and more3CompletedInsmedOct 28, 20241,767
NCT03218917Bronchiectasis · United States, Australia, Belgium and more2CompletedInsmedDec 12, 2019256
NCT02653872Healthy Subjects · United Kingdom1CompletedAstraZenecaApr 13, 201615
NCT02303574Safety, Pharmacokinetics, Pharmacodynamics, Food Effect · United Kingdom1CompletedAstraZenecaAug 3, 201689

How it is read

Names in the registry

  • “Brensocatib”, 10 entries
  • “Brensocatib 10 mg”, 2 entries
  • “Brensocatib 25 mg”, 2 entries
  • “Brensocatib Oral Solution”, 1 entry
  • “Brensocatib Oral Tablet”, 1 entry

Codes read as this program: AZD7986.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.